DDInter1494 DDInter1676
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Posaconazole {u} (Compound) resembles {v} (Compound) Itraconazole
Posaconazole {u} (Compound) binds {v} (Gene) ABCB1
Posaconazole {u} (Compound) is included by {v} (Pharmacologic Class) Azoles
Posaconazole {u} (Compound) causes {v} (Side Effect) Kidney function abnormal
Posaconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Posaconazole {u} may lead to a major life threatening interaction when taken with {v} Panobinostat
Posaconazole {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Posaconazole (Compound) resembles Itraconazole (Compound)
Posaconazole (Compound) binds ABCB1 (Gene)
Posaconazole (Compound) is included by Azoles (Pharmacologic Class)
Posaconazole (Compound) causes Kidney function abnormal (Side Effect)
Posaconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Posaconazole may lead to a major life threatening interaction when taken with Panobinostat
Posaconazole may lead to a major life threatening interaction when taken with Leflunomide